IPSC News and Press, Century Therapeutics Inc. From 04/12/23

2023-04-12 09:58:06 ET Century Therapeutics ( NASDAQ: IPSC ) said its Chief Executive Officer Lalo Flores had stepped down as Chief Executive Officer and as a member of the Board of Directors to pursue other opportunities. The company said it had appointed Chief Tech...

– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer – – Michael C. Diem, M.D., promoted to Chief Financial Officer ȁ...

2023-03-16 07:33:38 ET Century Therapeutics press release ( NASDAQ: IPSC ): FY GAAP EPS of -$2.27 beats by $0.05 . Revenue of $5.2M misses by $1.76M . For further details see: Century Therapeutics GAAP EPS of -$2.27 beats by $0.05, revenue of $5.2M misses...

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected into 2026 – PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) -- Century The...

PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company’s i...

– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch – – ELiPSE-1 trial to test multi-dosing strategy for CAR iNK e...

Listen on the go! Subscribe to Wall Street Breakfast on Apple Podcasts and Spotify Nonfarm payrolls report to provide insight into inflation , Fed policy. Raytheon (RTX) exploring $1B sale of actuation business - report. ChatGPT creator ...

Century Therapeutics ( NASDAQ: IPSC ) will lay off 25% of its workforce and prioritize certain programs in its pipeline in a move to extend its cash runway into 2026 . None of the cancer immunology-focused biotech's candidates are in the clinic. It is partnered with Bristol-Myers ...

- Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma - - Employee headcount reduced by approximately 25 percent, extending cash runway into 2026 - - Phase 1 stud...

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at...